Coronary artery disease, both obstructive and non-obstructive, often coexists with significant aortic stenosis. Therapeutic decision-making in this scenario remains controversial, not only regarding the need for treatment, but also about when it should be addressed, considering its pros and cons. Various analyses have yielded contradictory data, as most lesions are chronic and stable. Currently, the…
TAVI for Pure Aortic Valve Regurgitation Using a Newself-Expanding Technology | SOLACI-SBHCI 2023
✔️ SOLACI-SBHCI 2023 – International Live Case | TAVI for Pure Aortic Valve Regurgitation Using a Newself-Expanding Technology ✔️ Site: Nanjing First Hospital, Nanjing, China ✔️ August 4, 2023, Copacabana Room, Windsor Oceánico
TAVI with Commissural Alignment & Cerebral Protection | SOLACI-SBHCI 2023, International Live Case
✔️ SOLACI-SBHCI 2023 – Internationl Live Case | TAVI with Commissural Alignment & Cerebral Protection ✔️ Site; LEIPZIG HEART CENTER – LEIPZIG, GERMANY ✔️ August 3, 2023, Copacabana Room, Windsor Oceánico
TAVI Tailored Intermediate Bioprosthesis Sizes | SOLACI-SBHCI 2023 – National Live Case
✔️ SOLACI-SBHCI 2023 – National Live Case | TAVI Tailored Intermediate Bioprosthesis Sizes ✔️ Site; INSTITUTO ESTADUAL DE CARDIOLOGIA ALOYSIO DE CASTRO (IECAC) ✔️August 2, 2023, Copacabana Room, Windsor Oceánico
SAFE-TAVI Study: Safety and Efficacy of the Pressure Sensor and Pacing Guidewire
Currently, we observe an increase in the number of transcatheter aortic valve replacement (TAVR) procedures due to its expansion toward a younger population with lower risk. For this reason, it is crucial to maintain continuous technological innovation to minimize post-procedural complications. The FDA has approved the SavyWire, a preformed 0.035-caliber guidewire that offers three essential…
TAVI-in-TAVI with Balloon-Expandable Valves
TAVI (Transcatheter Aortic Valve Implantation) has proven to be beneficial and is currently performed in increasingly younger and lower-risk patients. However, as with surgical bioprostheses, structural deterioration, whether due to stenosis or regurgitation, is one of the challenges we must address. While currently uncommon, this is an issue we will probably see more and more…
Post-TAVI Prosthesis-Patient Mismatch
Prosthesis-patient mismatch (PPM) occurs when the effective orifice area (EOA) after valve placement is significantly smaller compared with the patient’s body surface area (BSA), resulting in an increased transprosthetic residual gradient. The presence of PPM, especially in various surgical series, has been associated with long-term adverse clinical events. In relation to transcatheter aortic valve implantation…
SCOPE I Results at 3 Years: ACURATE Neo vs. SAPIEN 3
Transcatheter aortic valve implantation (TAVI) has become the standard treatment for elderly patients with severe symptomatic aortic stenosis. While this has led to the development of new devices with different features, evidence from randomized studies on these new scaffolds is limited. The randomized SCOPE I study (Safety and Efficacy of the Symetis ACURATE Neo/TF Compared…
TCT 2022 | PROTECTED TAVR
Stroke is still a major complication of transcatheter aortic valve replacement (TAVR), with a 30-day mortality of 16.7%. Even in the absence of symptoms, most patients (68-93%) have some type of diffusion imaging defect after TAVR implantation. The Sentinel cerebral protection device (CPD) (Boston Scientific) received FDA approval for the capture of emboligenic material that…
The Best of the SOLACI-SOCIME 2022 Main Arena: Structural—Selected Topics of TAVR
On the last session from day 1 of SOLACI-SOCIME 2022 on structural pathology, Dr. Raj Makkar, an international expert on the subject, talked about transcatheter aortic valve replacement (TAVR) in pure aortic regurgitation (AR), which presents several implantation challenges, such as insufficient anchoring, embolization, residual regurgitation, ring rupture, etc. As opposed to patients with aortic…